Engineered Heart Repair

B. Fujita, W. H. Zimmermann*

*Corresponding author for this work
7 Citations (Scopus)


There is a pressing need for the development of advanced heart failure therapeutics. Current state-of-the-art is protection from neurohumoral overstimulation, which fails to address the underlying cause of heart failure, namely loss of cardiomyocytes. Implantation of stem cell-derived cardiomyocytes via tissue-engineered myocardium is being advanced to realize the remuscularization of the failing heart. Here, we discuss pharmacological challenges pertaining to the clinical translation of tissue-engineered heart repair with a focus on engineered heart muscle (EHM).

Original languageEnglish
JournalClinical Pharmacology and Therapeutics
Issue number2
Pages (from-to)197-199
Number of pages3
Publication statusPublished - 01.08.2017


Dive into the research topics of 'Engineered Heart Repair'. Together they form a unique fingerprint.

Cite this